Nephrologists Point to Profound Unmet Need for New Agents to Treat Glomerular Diseases Such as IgA Nephropathy, Focal Segmental Glomerulosclerosis (FSGS), and Lupus Nephritis
According to Spherix Global Insights, nephrologists anxiously await pipeline products such as Retrophin’s sparsentan, Aurinia’s voclosporin, Reata’s bardoxolone methyl, and Calliditas’ NEFECON to offer new options for patients suffering with these conditions EXTON, Pa., / August 31, 2020 / PRNewswire – Glomerular diseases pose some of the greatest challenges to nephrologists: they are progressive and […]
Nephrologists Are Hesitant to Fully Embrace Janssen’s INVOKANA Despite Being the First and Only SGLT2 Inhibitor with an FDA Indication to Treat Diabetic Kidney Disease
According to Spherix Global Insights’ latest quarterly survey of 101 US nephrologists, despite anticipated increases in use, over one-third of respondents still express some trepidation in prescribing INVOKANA EXTON, Pa., June 18, 2020 / PR Newswire / – Millions of patients across the United States suffer from Type 2 diabetes, and one-quarter or more of […]
Less Than One Year Post Launch, AbbVie’s Rinvoq Disrupts the Rheumatoid Arthritis Treatment Landscape, While a Rich Pipeline Waits in the Wings
The newest market entrant and possibly next autoimmune blockbuster has had an impressive launch so far, according to Spherix Global Insights EXTON, Pa., June 4, 2020 / PR Newswire / –The latest quarterly report included in Spherix’s RealTime Dynamix: Rheumatoid Arthritis (US) service captures the responses of 105 rheumatologists surveyed in May 2020 and highlights […]
COVID-19 Pandemic in the US May Curtail Uptake of Recent Acute Migraine Market Entrants, Diminishing Specialists’ Prelaunch Expectations that Biohaven’s Nurtec ODT Would Challenge Allergan’s Ubrelvy and Eli Lilly’s Reyvow
Looking to the future, the approval of the first dual-therapy migraine label would make Nurtec a substantial competitive threat on the prevention market, placing considerable stress on Amgen/Novartis’ Aimovig, Teva’s Ajovy, Eli Lilly’s Emgality, and Lundbeck’s Vyepti trajectories, according to Spherix Global Insights EXTON, Pa., April 2, 2020 ― Biohaven’s Nurtec (rimegepant) orally disintegrating tablet […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market
With a plethora of agents in development, manufacturers who already have one leg in the dermatology biologic/small molecule space, such as AbbVie, Amgen, Eli Lilly, Janssen, and Novartis could have a competitive edge over more novel developers. EXTON, Pa., March 17, 2020 /PRNewswire/ — The past decade has ushered in an array of new treatment […]
With Novartis’ Mayzent Firmly Positioned for Transitioning Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Use, EMD Serono’s Mavenclad Could Be Most Competitive as an Ideal First Switch Following Efficacy Failure
Bolstering Tecfidera’s competitiveness with the glatiramer acetate class among treatment-naïve relapsing-remitting multiple sclerosis patients is Biogen’s best defense against anticipated near-term share constriction, according to the 14th wave of the quarterly Spherix Global Insights report Download Report Overview EXTON, Pa., June 26, 2019 ― During the last week of March 2019, both Novartis’ Mayzent and […]
US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia’s Auryxia, Amgen’s Parsabiv, and Opko’s Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products
According to the latest quarterly update from Spherix Global Insights, strict protocols at large dialysis organizations (LDOs) are the leading barrier to increased use of Parsabiv while market access pressures remain the primary obstacle for Auryxia and Rayaldee. Download Report Overview JUNE 25, 2019, EXTON, PA – According to a survey of 202 nephrologists in […]
Sanofi/Regeneron’s Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment
With Dupixent only capturing a piece of the potential candidate pie, there remains ample runway for new agents in development to enter this highly dynamic market. Download Report Overview EXTON, Pa., Nov. 7, 2018 /PRNewswire/ – After over a year and a half on the market, U.S. dermatologists (n=102) remain extremely pleased with Sanofi/Regeneron’s Dupixent. In Spherix’s fourth quarter […]
In Multiple Myeloma, Janssen’s Darzalex Posted Significant Gains Over the Past Six Months, but May Face an Increasingly Restrictive Payer Environment
According to a new report from Spherix Global Insights, provider reimbursement anxiety and escalating out-of-pocket costs, as patients live longer and use these therapies for even more extended periods of time, are primary issues that could become barriers to increased use of Darzalex, although future projections still look strong. Download Report Overview Exton, PA. October […]
